VKTX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.903

+182.21%

-0.961

+134.45%

-0.999

+72.2%

Estimates Revision

The market is revising No Change the revenue expectations for Viking Therapeutics, Inc. (VKTX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 52.60%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+10.27%

In Past 3 Month

Stock Price

Go Up

+52.60%

In Past 3 Month

13 Analyst Rating

Wall Street analysts forecast VKTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VKTX is 97.27 USD with a low forecast of 70.00 USD and a high forecast of 125.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

13 Buy

0 Hold

0 Sell

Strong Buy

Current: 36.150

Low

70.00

Averages

97.27

High

125.00

Current: 36.150

Low

70.00

Averages

97.27

High

125.00

Canaccord

initiated

$106

2025-10-29

Reason

Canaccord

Price Target

$106

2025-10-29

initiated

Reason

Canaccord initiated coverage of Viking Therapeutics with a Buy rating and $106 price target.

Canaccord

Edward Nash

initiated

$106

2025-10-29

Reason

Canaccord

Edward Nash

Price Target

$106

2025-10-29

initiated

Reason

Canaccord analyst Edward Nash initiated coverage of Viking Therapeutics with a Buy rating and $106 price target. The firm views Viking as a leader in the obesity drug development space. It expects a readout from the company's two Phase 3 trials in 2027 and mid-2028, respectively. Viking also reported "strong" efficacy Phase 2 data in August from the oral version of VK2735, the analyst tells investors in a research note. Canaccord believes the drug can differentiate on "multiple fronts."

JPMorgan

Overweight

downgrade

$80 -> $75

2025-10-24

Reason

JPMorgan

Price Target

$80 -> $75

2025-10-24

downgrade

Overweight

Reason

JPMorgan lowered the firm's price target on Viking Therapeutics to $75 from $80 and keeps an Overweight rating on the shares.

Morgan Stanley

Overweight

maintain

$98 -> $102

2025-10-23

Reason

Morgan Stanley

Price Target

$98 -> $102

2025-10-23

maintain

Overweight

Reason

Morgan Stanley raised the firm's price target on Viking Therapeutics to $102 from $98 and keeps an Overweight rating on the shares. The VANQUISH-1 obesity and VANQUISH-2 Type 2 diabetes plus obesity trials are enrolling ahead of schedule, notes the analyst, who also notes that management plans to meet with the FDA in an end-of-Phase 2 meeting for oral VK2735 in Q4 with a Phase 3 start targeted soon after. The firm is "encouraged by swift execution across programs," the analyst tells investors after the company's Q3 update.

Cantor Fitzgerald

Overweight

maintain

$105

2025-10-23

Reason

Cantor Fitzgerald

Price Target

$105

2025-10-23

maintain

Overweight

Reason

Cantor Fitzgerald tells investors after Viking Therapeutics' "transformative" Q3 update that "this was the most bullish update Viking has given since we started covering the stock more than 7 years ago." Viking "just crystallized five critically important data catalysts in the next 24 months" and the company affirmed cash on hand of greater than $700M was sufficient to get through all of them, according to the analyst, who has an Overweight rating and $105 price target on Viking shares.

B. Riley

Buy

maintain

$85

2025-08-20

Reason

B. Riley

Price Target

$85

2025-08-20

maintain

Buy

Reason

B. Riley views the selloff in shares of Viking Therapeutics following VK2735 oral weight loss data as overdone. The pullback indicates the dataset disappointed investor expectations, particularly as cross-trial comparisons are being made to Eli Lilly's (LLY) oral GLP1 orforglipron, the analyst tells investors in a research note. Riley's base case of oral VK2735 remaining important to the maintenance therapy phase is unchanged. It reiterates a Buy rating on Viking with an $85 price target. The stock closed Tuesday down 42% to $24.363.

Valuation Metrics

The current forward P/E ratio for Viking Therapeutics Inc (VKTX.O) is -9.27, compared to its 5-year average forward P/E of -17.54. For a more detailed relative valuation and DCF analysis to assess Viking Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-17.54

Current PE

-9.27

Overvalued PE

0.01

Undervalued PE

-35.10

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-12.22

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.47

Undervalued EV/EBITDA

-25.91

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

209.77

Current PS

0.00

Overvalued PS

796.30

Undervalued PS

-376.76

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 299.39% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 299.39% over the last month.

Sold

Bought

VKTX News & Events

Events Timeline

No data

News

6.5

04:11 AMYahoo Finance

Canaccord Calls Viking Therapeutics (VKTX) 'Highly Appealing' and Undervalued, Recognizing Its Leadership in Obesity Clinical Development

2.0

12-15NASDAQ.COM

Viking Therapeutics, Inc. (VKTX) Experiences a Larger Decline Than the Market: Key Points to Consider

8.0

12-12NASDAQ.COM

Significant Options Trading on Friday: WMT, VKTX, DPZ

People Also Watch

Frequently Asked Questions

What is Viking Therapeutics Inc (VKTX) stock price today?

The current price of VKTX is 36.15 USD — it has decreased -2.51 % in the last trading day.

What is Viking Therapeutics Inc (VKTX)'s business?

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.

What is the price predicton of VKTX Stock?

What is Viking Therapeutics Inc (VKTX)'s revenue for the last quarter?

Viking Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Viking Therapeutics Inc (VKTX)'s earnings per share (EPS) for the last quarter?

Viking Therapeutics Inc. EPS for the last quarter amounts to -0.81 USD, increased 268.18 % YoY.

What changes have occurred in the market's expectations for Viking Therapeutics Inc (VKTX)'s fundamentals?

How many employees does Viking Therapeutics Inc (VKTX). have?

Viking Therapeutics Inc (VKTX) has 36 emplpoyees as of December 16 2025.

What is Viking Therapeutics Inc (VKTX) market cap?

Today VKTX has the market capitalization of 4.09B USD.